ALOPM Share Price Performance
€0.47
-0.83 (-64.23%)
Price €0.47
Share Price€0.47
Oncodesign Precision Medicine Société anonyme Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ALOPM Community Narratives
There are no narratives available yet.
Recent ALOPM News & Updates
Oncodesign Precision Medicine Société anonyme Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.35
- Gross Margin
- 536.76%
- Net Profit Margin
- 361.97%
- Debt/Equity Ratio
- -1,765.5%
Oncodesign Precision Medicine Société anonyme Competitors
Snowflake Analysis
About ALOPM
- Founded
- 1995
- Employees
- 18
- CEO
- WebsiteView website
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease. It is also developing drugs for the treatment of pancreatic and other cancers. The company has a strategic collaboration agreement with Navigo Proteins GmbH for the discovery and development of new systemic radiotheranostic agents. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
French Market Performance
- 7 Days: 1.6%
- 3 Months: 1.3%
- 1 Year: 5.2%
- Year to Date: 7.3%
The market has climbed 1.6% in the last 7 days, lead by the Consumer Discretionary sector with a gain of 6.5%. As for the past 12 months, the market is up 5.2%. Earnings are forecast to grow by 12% annually. Market details ›